tiprankstipranks
Advertisement
Advertisement
Akebia (AKBA): Buy Rating Backed by Vafseo Momentum and High-Value Renal Pipeline Upside
PremiumRatingsAkebia (AKBA): Buy Rating Backed by Vafseo Momentum and High-Value Renal Pipeline Upside
2M ago
Akebia Therapeutics Earnings Call: Vafseo Drives Growth
Premium
Company Announcements
Akebia Therapeutics Earnings Call: Vafseo Drives Growth
3M ago
3 Best Stocks to Buy Today with 125%+ Upside, 2/27/2026, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Today with 125%+ Upside, 2/27/2026, According to Top Analysts
3M ago
Akebia price target lowered to $4 from $6 at Piper Sandler
PremiumThe FlyAkebia price target lowered to $4 from $6 at Piper Sandler
4M ago
Akebia Therapeutics Updates Executive Severance and Leadership Terms
Premium
Company Announcements
Akebia Therapeutics Updates Executive Severance and Leadership Terms
4M ago
Akebia announces corporate updates, 2026 pipeline outlook
Premium
The Fly
Akebia announces corporate updates, 2026 pipeline outlook
5M ago
Akebia Therapeutics Acquires Global Rights to ADX-097
PremiumCompany AnnouncementsAkebia Therapeutics Acquires Global Rights to ADX-097
6M ago
Akebia Therapeutics announces establishment of rare kidney disease pipeline
Premium
The Fly
Akebia Therapeutics announces establishment of rare kidney disease pipeline
6M ago
Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront
Premium
The Fly
Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100